Compare JYD & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYD | SNTI |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 10.4M |
| IPO Year | 2022 | 2021 |
| Metric | JYD | SNTI |
|---|---|---|
| Price | $1.65 | $0.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $127.27 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.47 | $0.15 |
| 52 Week High | $5.75 | $57.60 |
| Indicator | JYD | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 14.40 |
| Support Level | $0.65 | N/A |
| Resistance Level | $2.12 | $7.00 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 51.69 | 27.58 |
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, fragmented logistics, and chartered airline freight services, supply chain management, and other value-added services.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).